FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997694917> ?p ?o ?g. }

• W1997694917 endingPage "331" @default.
• W1997694917 startingPage "325" @default.
• W1997694917 abstract "This short-term, single-blind, pilot trial was initiated to investigate the usefulness of quetiapine therapy in the treatment of schizophrenic patients refractory to first-generation antipsychotics. Following a neuroleptic-free period prior to study entry (at least 1 week for oral formulations and 6 weeks for depot formulations), quetiapine was started at 50 mg/day and titrated up to 500 mg/day by Day 6. This 500 mg daily dose was then maintained or increased up to a maximum of 750 mg/day, at the discretion of the treating physician, who was aware of the antipsychotic prescribed. Efficacy measures were represented by changes in total and component PANSS score from baseline to different intervals. Safety and tolerability were evaluated by monitoring the spontaneously referred moderate-to-severe adverse events, changes from baseline in SAS, BARS, and AIMS scores, supplementary use of flurazepam, lorazepam, and benztropine, clinically relevant physical changes, abnormalities in vital signs, blood chemistry, and hematology, and modifications in QTc interval and body weight. Rating scale assessments, categorization of adverse events, determination of physical examination, vital signs, and body weight were performed by a qualified physician blind to the particular antipsychotic under investigation and the aims of the study. All 12 patients completed the 4-week quetiapine treatment course. Mean total PANSS scores were significantly reduced between baseline and study endpoint (p=0.006). Five out of six PANSS subcomponent scores also showed significant decreases (p < 0.05). Six patients showed a reduction of > or = 20% in PANSS total score by the final day of quetiapine treatment, so were classified as responders. There were responders in all schizophrenia diagnostic subgroups (undifferentiated, paranoid, and disorganized). Two patients reported moderate adverse events. One patient received 3 days of benztropine therapy for EPS and five received flurazepam for insomnia. Weight change was minimal and mean SAS, BARS, and AIMS scores all showed nonsignificant decreases between baseline and endpoint. The 50% quetiapine response rate reported here in refractory patients is comparable with those previously reported for other atypical antipsychotics in populations of both refractory and intolerant patients." @default.
• W1997694917 created "2016-06-24" @default.
• W1997694917 creator A5015394961 @default.
• W1997694917 creator A5061128012 @default.
• W1997694917 creator A5072358499 @default.
• W1997694917 creator A5085452079 @default.
• W1997694917 date "2004-08-01" @default.
• W1997694917 modified "2023-09-23" @default.
• W1997694917 title "Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial" @default.
• W1997694917 cites W1821837697 @default.
• W1997694917 cites W1900361016 @default.
• W1997694917 cites W1984513132 @default.
• W1997694917 cites W1988897630 @default.
• W1997694917 cites W1992673841 @default.
• W1997694917 cites W1998569805 @default.
• W1997694917 cites W1999689270 @default.
• W1997694917 cites W2009026422 @default.
• W1997694917 cites W2013572521 @default.
• W1997694917 cites W2014659268 @default.
• W1997694917 cites W2019879674 @default.
• W1997694917 cites W2024266917 @default.
• W1997694917 cites W2029299542 @default.
• W1997694917 cites W2031786430 @default.
• W1997694917 cites W2039163742 @default.
• W1997694917 cites W2040559929 @default.
• W1997694917 cites W2044907929 @default.
• W1997694917 cites W2060802427 @default.
• W1997694917 cites W2069505586 @default.
• W1997694917 cites W2079999567 @default.
• W1997694917 cites W2081095472 @default.
• W1997694917 cites W2083680124 @default.
• W1997694917 cites W2084254534 @default.
• W1997694917 cites W2085360366 @default.
• W1997694917 cites W2115115146 @default.
• W1997694917 cites W2125778283 @default.
• W1997694917 cites W2133602373 @default.
• W1997694917 cites W2140606211 @default.
• W1997694917 cites W2154125298 @default.
• W1997694917 cites W2162089381 @default.
• W1997694917 cites W2165379748 @default.
• W1997694917 cites W2170201623 @default.
• W1997694917 cites W2329708303 @default.
• W1997694917 cites W43076824 @default.
• W1997694917 cites W940697911 @default.
• W1997694917 doi "https://doi.org/10.1016/s0920-9964(03)00225-1" @default.
• W1997694917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15469204" @default.
• W1997694917 hasPublicationYear "2004" @default.
• W1997694917 type Work @default.
• W1997694917 sameAs 1997694917 @default.
• W1997694917 citedByCount "16" @default.
• W1997694917 countsByYear W19976949172014 @default.
• W1997694917 countsByYear W19976949172015 @default.
• W1997694917 countsByYear W19976949172017 @default.
• W1997694917 countsByYear W19976949172023 @default.
• W1997694917 crossrefType "journal-article" @default.
• W1997694917 hasAuthorship W1997694917A5015394961 @default.
• W1997694917 hasAuthorship W1997694917A5061128012 @default.
• W1997694917 hasAuthorship W1997694917A5072358499 @default.
• W1997694917 hasAuthorship W1997694917A5085452079 @default.
• W1997694917 hasConcept C118552586 @default.
• W1997694917 hasConcept C126322002 @default.
• W1997694917 hasConcept C197934379 @default.
• W1997694917 hasConcept C203092338 @default.
• W1997694917 hasConcept C2776412080 @default.
• W1997694917 hasConcept C2777393122 @default.
• W1997694917 hasConcept C2778375690 @default.
• W1997694917 hasConcept C2779706987 @default.
• W1997694917 hasConcept C2780494398 @default.
• W1997694917 hasConcept C2780634440 @default.
• W1997694917 hasConcept C42219234 @default.
• W1997694917 hasConcept C535046627 @default.
• W1997694917 hasConcept C71924100 @default.
• W1997694917 hasConceptScore W1997694917C118552586 @default.
• W1997694917 hasConceptScore W1997694917C126322002 @default.
• W1997694917 hasConceptScore W1997694917C197934379 @default.
• W1997694917 hasConceptScore W1997694917C203092338 @default.
• W1997694917 hasConceptScore W1997694917C2776412080 @default.
• W1997694917 hasConceptScore W1997694917C2777393122 @default.
• W1997694917 hasConceptScore W1997694917C2778375690 @default.
• W1997694917 hasConceptScore W1997694917C2779706987 @default.
• W1997694917 hasConceptScore W1997694917C2780494398 @default.
• W1997694917 hasConceptScore W1997694917C2780634440 @default.
• W1997694917 hasConceptScore W1997694917C42219234 @default.
• W1997694917 hasConceptScore W1997694917C535046627 @default.
• W1997694917 hasConceptScore W1997694917C71924100 @default.
• W1997694917 hasIssue "2-3" @default.
• W1997694917 hasLocation W19976949171 @default.
• W1997694917 hasLocation W19976949172 @default.
• W1997694917 hasOpenAccess W1997694917 @default.
• W1997694917 hasPrimaryLocation W19976949171 @default.
• W1997694917 hasRelatedWork W1922671966 @default.
• W1997694917 hasRelatedWork W1970566540 @default.
• W1997694917 hasRelatedWork W2022845991 @default.
• W1997694917 hasRelatedWork W2023009965 @default.
• W1997694917 hasRelatedWork W2032448496 @default.
• W1997694917 hasRelatedWork W2056313943 @default.
• W1997694917 hasRelatedWork W2065273492 @default.
• W1997694917 hasRelatedWork W2070696665 @default.

• next